The FORECAST study - Focal recurrent assessment and salvage treatment for radiorecurrent prostate cancer.

[1]  Y. Yamada,et al.  The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. , 2015, European urology.

[2]  J. Jones,et al.  Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: Initial results from the cryo on‐line data registry , 2015, The Prostate.

[3]  Nathan Lawrentschuk,et al.  The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review , 2014, European urology.

[4]  P. Schellhammer,et al.  Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. , 2014, European urology.

[5]  N. Sathianathen,et al.  Outcomes of artificial urinary sphincter implantation in the irradiated patient , 2014, BJU international.

[6]  P. Wiklund,et al.  Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes , 2014, BMJ : British Medical Journal.

[7]  S. Fanti,et al.  11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  N. Ruel,et al.  Radiation history affects continence outcomes after advance transobturator sling placement in patients with post-prostatectomy incontinence. , 2013, Urology.

[9]  I. Gill,et al.  Salvage focal and salvage total cryoablation for locally recurrent prostate cancer after primary radiation therapy , 2013, BJU international.

[10]  A. Mundy,et al.  Conservative management of urorectal fistulae. , 2013, Urology.

[11]  C. Roy,et al.  Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy. , 2013, AJR. American journal of roentgenology.

[12]  H. Ahmed,et al.  717 Transperineal MRI-targeted biopsy versus transperineal template prostate mapping biopsy in the detection of localised radio-recurrent prostate cancer , 2013 .

[13]  B. Herts,et al.  Rectourethral fistula after salvage cryotherapy for prostate adenocarcinoma. , 2013, The Journal of urology.

[14]  D. Neal,et al.  Androgen deprivation treatment in prostate cancer , 2013, BMJ.

[15]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[16]  H. Payne,et al.  Hormone therapy for radiorecurrent prostate cancer , 2013, World Journal of Urology.

[17]  D. Dearnaley,et al.  Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. , 2012, AJR. American journal of roentgenology.

[18]  H. Ahmed,et al.  Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy , 2012, Cancer.

[19]  A. Adler,et al.  NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. , 2012, The Lancet. Oncology.

[20]  A. Mundy,et al.  Posterior urethral complications of the treatment of prostate cancer , 2012, BJU international.

[21]  Laurence Collette,et al.  Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? , 2012, European urology.

[22]  J. Chin,et al.  Whole‐gland salvage high‐intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy , 2012, Cancer.

[23]  V. Mouraviev,et al.  Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. , 2012, European urology.

[24]  John Kurhanewicz,et al.  Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer , 2012, BJU international.

[25]  P. Scardino,et al.  Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. , 2012, European urology.

[26]  K. Stein,et al.  Cost‐effectiveness analysis of degarelix for advanced hormone‐dependent prostate cancer , 2012, BJU international.

[27]  Zeike A. Taylor,et al.  MR to ultrasound registration for image-guided prostate interventions , 2012, Medical Image Anal..

[28]  P. Maki,et al.  Cognitive changes associated with ADT: a review of the literature. , 2012, Asian journal of andrology.

[29]  C. Sternberg,et al.  Contemporary role of androgen deprivation therapy for prostate cancer. , 2012, European urology.

[30]  G. Beaudoin,et al.  Towards dose reduction in CT: patient radiation dose assessment for CT examinations at university health center in Canada and comparison with national diagnostic reference levels. , 2012, Radiation protection dosimetry.

[31]  Matthias Eiber,et al.  Whole‐body MRI including diffusion‐weighted imaging (DWI) for patients with recurring prostate cancer: Technical feasibility and assessment of lesion conspicuity in DWI , 2011, Journal of magnetic resonance imaging : JMRI.

[32]  A. Mundy,et al.  Urorectal fistulae following the treatment of prostate cancer , 2011, BJU international.

[33]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[34]  M. Özmen,et al.  The value of dynamic contrast-enhanced MRI in the detection of recurrent prostate cancer after external beam radiotherapy: correlation with transrectal ultrasound and pathological findings. , 2011, Diagnostic and interventional radiology.

[35]  Clare Allen,et al.  Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy , 2010, BJU international.

[36]  V. Mouraviev,et al.  Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy , 2010, BJU international.

[37]  David J. Hawkes,et al.  MR to Ultrasound Image Registration for Guiding Prostate Biopsy and Interventions , 2009, MICCAI.

[38]  A. Sidana,et al.  Cyclophosphamide Unmasks an Antimetastatic Effect of Local Tumor Cryoablation , 2009, Journal of Pharmacology and Experimental Therapeutics.

[39]  J. Chin,et al.  Salvage HIFU for recurrent prostate cancer after radiotherapy , 2009, Prostate Cancer and Prostatic Diseases.

[40]  D. Karan,et al.  CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. , 2009, Advanced drug delivery reviews.

[41]  J. Chapelon,et al.  Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. , 2009, European urology.

[42]  B. Donnelly,et al.  Salvage prostate cryoablation: initial results from the cryo on-line data registry. , 2008, The Journal of urology.

[43]  X. Rébillard,et al.  High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology , 2008, BJU international.

[44]  Masoom A Haider,et al.  Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[45]  Dow-Mu Koh,et al.  Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. , 2007, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[46]  M. Melamed,et al.  Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience. , 2007, Urology.

[47]  I. Derweesh,et al.  Risk of new‐onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen‐deprivation therapy for prostate cancer , 2007, BJU international.

[48]  Shwan Ahmed,et al.  Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients , 2007, BJU international.

[49]  D. Downey,et al.  Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. , 2007, The Journal of urology.

[50]  A. D'Amico,et al.  Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate‐specific antigen failure , 2007, Cancer.

[51]  M. Schonlau,et al.  Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer , 2007, Cancer.

[52]  H. Hricak,et al.  Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. , 2007, International journal of radiation oncology, biology, physics.

[53]  I. Narabayashi,et al.  2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience , 2007, Annals of nuclear medicine.

[54]  F. Lugnani,et al.  Salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. , 2007, Journal of endourology.

[55]  K. Wallner,et al.  Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. , 2006, European urology.

[56]  M. Schwaiger,et al.  The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  V. Master,et al.  Management of severe urethral complications of prostate cancer therapy. , 2006, The Journal of urology.

[58]  J. Simons,et al.  Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. , 2006, Urologic oncology.

[59]  A. Dobs,et al.  Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[61]  Susan Michie,et al.  Developing and Evaluating Complex Interventions , 2015 .

[62]  David E. Stein,et al.  Management of radiotherapy induced rectourethral fistula. , 2006, The Journal of urology.

[63]  Holly T. Sullivan,et al.  Clinical staging of prostate cancer: a computer‐simulated study of transperineal prostate biopsy , 2005, BJU international.

[64]  P. Scardino,et al.  Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[65]  S. Ahmed,et al.  Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy , 2005, Prostate Cancer and Prostatic Diseases.

[66]  J. Chin,et al.  Current status of local salvage therapies following radiation failure for prostate cancer. , 2005, The Journal of urology.

[67]  J. Goodwin,et al.  Risk of fracture after androgen deprivation for prostate cancer. , 2005, The New England journal of medicine.

[68]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[69]  L. Curiel,et al.  Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. , 2004, Urology.

[70]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[71]  N. Bander,et al.  Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. , 2003, The Journal of urology.

[72]  D. Kuban,et al.  Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. , 2003, International journal of radiation oncology, biology, physics.

[73]  S. Saji,et al.  Antitumor effects of residual tumor after cryoablation: the combined effect of residual tumor and a protein-bound polysaccharide on multiple liver metastases in a murine model. , 2003, Cryobiology.

[74]  D. Kuban,et al.  Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. , 2002, The Journal of urology.

[75]  J. Stanford,et al.  Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  Adalsteinn D. Brown,et al.  Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. , 2000, Journal of the National Cancer Institute.

[77]  G. Perry,et al.  Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. , 2000, International journal of radiation oncology, biology, physics.

[78]  J. Blasko,et al.  Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. , 2000, Seminars in urologic oncology.

[79]  A. K. Levinson,et al.  Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. , 2000, Journal of Urology.

[80]  D. Kuban,et al.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. , 1999, JAMA.

[81]  G. Swanson,et al.  Salvage brachytherapy for localized prostate cancer after radiotherapy failure. , 1999, Urology.

[82]  M. D'Angelica,et al.  The effects of hepatic cryosurgery on tumor growth in the liver. , 1998, The Journal of surgical research.

[83]  A. Hanlon,et al.  Conformai external beam treatment of prostate cancer , 1997 .

[84]  M. Scholz,et al.  Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. , 1997, British journal of urology.

[85]  G E Hanks,et al.  Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  P. Schellhammer,et al.  Reevaluation of prostate biopsy after definitive radiation therapy. , 1993, Urology.

[87]  S. Saji,et al.  Experimental study on mechanism of absorption of cryonecrotized tumor antigens. , 1987, Cryobiology.

[88]  D. Bostwick,et al.  Radiation injury of the normal and neoplastic prostate , 1982, The American journal of surgical pathology.

[89]  T. Yamashita,et al.  Enhanced tumor metastases in rats following cryosurgery of primary tumor. , 1982, Gan.

[90]  S. Saji,et al.  Late appearance of resistance to tumor rechallenge following cryosurgery. A study in an experimental mammary tumor of the rat. , 1981, Cryobiology.

[91]  H. B. Neel,et al.  Experimental evaluation of in situ oncocide for primary tumor therapy: Comparison of tumor‐specific immunity after complete excision, cryonecrosis and ligation , 1973, The Laryngoscope.

[92]  C. Blackwood,et al.  Response of experimental tumor systems to cryosurgery. , 1972, Cryobiology.

[93]  D. Wilkins.  Screening for inherited metabolic diseases. , 1972, British medical journal.

[94]  W. A. Soanes,et al.  A possible immuno-cryothermic response in prostatic cancer. , 1970, Clinical radiology.

[95]  S. Shulman,et al.  Studies in cryo-immunology. II. Tissue and species specificity of the autoantibody response and comparison with iso-immunization. , 1968, Immunology.

[96]  F. T. Moore,et al.  Cryotherapy for malignant tumors. , 1967, Cryobiology.

[97]  W. A. Soanes,et al.  Studies in cryo-immunology. I. The production of antibodies to urogenital tissue in consequence of freezing treatment. , 1967, Immunology.